Study to Investigate the Efficacy, Safety, and Tolerability of the Bi-specific T-cell Engager (BiTE®) MT103 in Patients with Minimal Residual Disease (MRD) of Positive B-precursor Acute Lymphoblastic Leukemia (ALL)

Sponsor ID

MT103-202

Clinicaltrials.gov ID

EUCTIS ID

N/A

EudraCT ID

N/A

Study Details

Phase

Phase 2

Product

blinatumomab

Type

Interventional

Masking

N/A

Enrollment

N/A

Additional Study Details

Primary Outcome Measures

Not Available

Secondary Outcome Measures

Not Available

Study Synopsis

Available Language(s): English

No locations found.